Jasper Total Assets vs Total Liab Analysis

JSPR Stock

USD 23.10 0.13 0.56%

Jasper Therapeutics financial indicator trend analysis is infinitely more than just investigating Jasper Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jasper Therapeutics is a good investment. Please check the relationship between Jasper Therapeutics Total Assets and its Total Liab accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jasper Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Jasper Stock, please use our How to Invest in Jasper Therapeutics guide.

Total Assets vs Total Liab

Total Assets vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jasper Therapeutics Total Assets account and Total Liab. At this time, the significance of the direction appears to have very week relationship.

The correlation between Jasper Therapeutics' Total Assets and Total Liab is 0.27. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Total Liab in the same time period over historical financial statements of Jasper Therapeutics, assuming nothing else is changed. The correlation between historical values of Jasper Therapeutics' Total Assets and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Jasper Therapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Total Assets i.e., Jasper Therapeutics' Total Assets and Total Liab go up and down completely randomly.

Correlation Coefficient

0.27

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Total Assets

Total assets refers to the total amount of Jasper Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Jasper Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Jasper Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jasper Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jasper Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Jasper Stock, please use our How to Invest in Jasper Therapeutics guide.As of 05/22/2024, Selling General Administrative is likely to drop to about 11.2 M. In addition to that, Issuance Of Capital Stock is likely to drop to about 61.9 M

	2010	2023	2024 (projected)
Interest Income	701K	5.2M	3.2M
Net Interest Income	701K	5.2M	3.2M

Interest Income Net Interest Income

Jasper Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Warrants	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Retained Earnings Total Equity	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Long Term Investments	Total Current Assets	Non Current Liabilities Other
Total Assets		0.59	0.93	0.83	0.27	-0.79	-0.78	-0.96	-0.81	0.98	1.0	0.85	0.85	0.38	1.0	0.92	-0.83	-0.53	-0.05	0.92	0.85	0.88	0.27	0.7	1.0	0.52
Other Current Liab	0.59		0.79	0.6	-0.41	-0.83	-0.86	-0.67	-0.94	0.64	0.56	0.72	0.76	-0.23	0.56	0.65	-0.8	-0.88	-0.05	0.66	0.49	0.88	0.29	0.9	0.57	-0.29
Total Current Liabilities	0.93	0.79		0.71	0.09	-0.94	-0.91	-0.87	-0.94	0.96	0.9	0.94	0.96	0.25	0.9	0.95	-0.92	-0.6	0.08	0.95	0.81	0.91	0.42	0.8	0.91	0.28
Total Stockholder Equity	0.83	0.6	0.71		-0.11	-0.63	-0.58	-0.9	-0.73	0.73	0.85	0.61	0.58	-0.05	0.85	0.74	-0.74	-0.68	-0.54	0.73	0.71	0.85	-0.2	0.69	0.84	0.28
Other Liab	0.27	-0.41	0.09	-0.11		0.09	-0.1	-0.17	0.14	0.33	0.27	0.19	0.15	0.98	0.27	0.14	0.03	0.33	0.61	0.14	0.28	-0.06	0.55	-0.33	0.28	0.85
Net Tangible Assets	-0.79	-0.83	-0.94	-0.63	0.09		0.88	0.72	0.94	-0.82	-0.74	-0.96	-0.97	-0.08	-0.74	-0.94	0.97	0.56	-0.04	-0.94	-0.83	-0.85	-0.37	-0.71	-0.76	-0.15
Warrants	-0.78	-0.86	-0.91	-0.58	-0.1	0.88		0.8	0.95	-0.87	-0.74	-0.91	-0.94	-0.29	-0.74	-0.81	0.89	0.75	-0.29	-0.82	-0.73	-0.91	-0.63	-0.76	-0.75	-0.17
Net Debt	-0.96	-0.67	-0.87	-0.9	-0.17	0.72	0.8		0.84	-0.93	-0.96	-0.78	-0.77	-0.28	-0.96	-0.83	0.8	0.72	0.13	-0.82	-0.77	-0.94	-0.22	-0.77	-0.96	-0.4
Retained Earnings	-0.81	-0.94	-0.94	-0.73	0.14	0.94	0.95	0.84		-0.85	-0.78	-0.9	-0.92	-0.04	-0.78	-0.86	0.94	0.81	0.0	-0.87	-0.74	-0.97	-0.38	-0.86	-0.79	-0.05
Accounts Payable	0.98	0.64	0.96	0.73	0.33	-0.82	-0.87	-0.93	-0.85		0.96	0.9	0.9	0.46	0.96	0.91	-0.84	-0.55	0.14	0.91	0.82	0.88	0.46	0.71	0.97	0.49
Cash	1.0	0.56	0.9	0.85	0.27	-0.74	-0.74	-0.96	-0.78	0.96		0.8	0.79	0.37	1.0	0.88	-0.78	-0.53	-0.09	0.88	0.8	0.86	0.22	0.7	1.0	0.51
Non Current Assets Total	0.85	0.72	0.94	0.61	0.19	-0.96	-0.91	-0.78	-0.9	0.9	0.8		0.99	0.35	0.8	0.96	-0.96	-0.5	0.19	0.97	0.91	0.84	0.51	0.6	0.82	0.4
Non Currrent Assets Other	0.85	0.76	0.96	0.58	0.15	-0.97	-0.94	-0.77	-0.92	0.9	0.79	0.99		0.33	0.79	0.94	-0.95	-0.54	0.23	0.95	0.86	0.85	0.55	0.66	0.81	0.32
Other Assets	0.38	-0.23	0.25	-0.05	0.98	-0.08	-0.29	-0.28	-0.04	0.46	0.37	0.35	0.33		0.37	0.27	-0.12	0.19	0.69	0.27	0.38	0.09	0.69	-0.19	0.37	0.82
Cash And Short Term Investments	1.0	0.56	0.9	0.85	0.27	-0.74	-0.74	-0.96	-0.78	0.96	1.0	0.8	0.79	0.37		0.88	-0.78	-0.53	-0.09	0.88	0.8	0.86	0.22	0.7	1.0	0.51
Common Stock Total Equity	0.92	0.65	0.95	0.74	0.14	-0.94	-0.81	-0.83	-0.86	0.91	0.88	0.96	0.94	0.27	0.88		-0.95	-0.45	-0.03	1.0	0.94	0.84	0.3	0.62	0.9	0.45
Retained Earnings Total Equity	-0.83	-0.8	-0.92	-0.74	0.03	0.97	0.89	0.8	0.94	-0.84	-0.78	-0.96	-0.95	-0.12	-0.78	-0.95		0.62	0.05	-0.95	-0.91	-0.89	-0.31	-0.67	-0.8	-0.27
Short Term Investments	-0.53	-0.88	-0.6	-0.68	0.33	0.56	0.75	0.72	0.81	-0.55	-0.53	-0.5	-0.54	0.19	-0.53	-0.45	0.62		0.16	-0.45	-0.36	-0.85	-0.17	-0.85	-0.53	0.24
Non Current Liabilities Total	-0.05	-0.05	0.08	-0.54	0.61	-0.04	-0.29	0.13	0.0	0.14	-0.09	0.19	0.23	0.69	-0.09	-0.03	0.05	0.16		-0.01	-0.04	-0.1	0.92	-0.15	-0.08	0.19
Capital Surpluse	0.92	0.66	0.95	0.73	0.14	-0.94	-0.82	-0.82	-0.87	0.91	0.88	0.97	0.95	0.27	0.88	1.0	-0.95	-0.45	-0.01		0.93	0.84	0.31	0.62	0.89	0.44
Other Current Assets	0.85	0.49	0.81	0.71	0.28	-0.83	-0.73	-0.77	-0.74	0.82	0.8	0.91	0.86	0.38	0.8	0.94	-0.91	-0.36	-0.04	0.93		0.74	0.26	0.38	0.82	0.63
Other Stockholder Equity	0.88	0.88	0.91	0.85	-0.06	-0.85	-0.91	-0.94	-0.97	0.88	0.86	0.84	0.85	0.09	0.86	0.84	-0.89	-0.85	-0.1	0.84	0.74		0.28	0.88	0.87	0.15
Total Liab	0.27	0.29	0.42	-0.2	0.55	-0.37	-0.63	-0.22	-0.38	0.46	0.22	0.51	0.55	0.69	0.22	0.3	-0.31	-0.17	0.92	0.31	0.26	0.28		0.17	0.24	0.23
Long Term Investments	0.7	0.9	0.8	0.69	-0.33	-0.71	-0.76	-0.77	-0.86	0.71	0.7	0.6	0.66	-0.19	0.7	0.62	-0.67	-0.85	-0.15	0.62	0.38	0.88	0.17		0.7	-0.24
Total Current Assets	1.0	0.57	0.91	0.84	0.28	-0.76	-0.75	-0.96	-0.79	0.97	1.0	0.82	0.81	0.37	1.0	0.9	-0.8	-0.53	-0.08	0.89	0.82	0.87	0.24	0.7		0.52
Non Current Liabilities Other	0.52	-0.29	0.28	0.28	0.85	-0.15	-0.17	-0.4	-0.05	0.49	0.51	0.4	0.32	0.82	0.51	0.45	-0.27	0.24	0.19	0.44	0.63	0.15	0.23	-0.24	0.52

Click cells to compare fundamentals

Jasper Therapeutics Account Relationship Matchups

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Jasper Therapeutics is a strong investment it is important to analyze Jasper Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Jasper Therapeutics' future performance. For an informed investment choice regarding Jasper Stock, refer to the following important reports:

How To Invest In Jasper

Details

Is Jasper Stock a good investment?

Details

What is Jasper Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jasper Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Jasper Stock, please use our How to Invest in Jasper Therapeutics guide.

You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for Jasper Stock analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing

Is Jasper Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Jasper Therapeutics. If investors know Jasper will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Jasper Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(61.80)

Return On Assets

(0.60)

Return On Equity

(1.13)

The market value of Jasper Therapeutics is measured differently than its book value, which is the value of Jasper that is recorded on the company's balance sheet. Investors also form their own opinion of Jasper Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Jasper Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Jasper Therapeutics' market value can be influenced by many factors that don't directly affect Jasper Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Jasper Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Jasper Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Jasper Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Jasper Total Assets vs Total Liab Analysis

Total Assets vs Total Liab

Total Assets vs Total Liab Correlation Analysis

Correlation Coefficient

Total Assets

Total Liab

Jasper Therapeutics fundamental ratios Correlations

Jasper Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Jasper Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Other Stockholder Equity	- 0.97	Retained Earnings
Non Currrent Assets Other	- 0.97	Net Tangible Assets
Retained Earnings Total Equity	- 0.96	Non Current Assets Total
Total Current Assets	- 0.96	Net Debt
Cash And Short Term Investments	- 0.96	Net Debt
Cash	- 0.96	Net Debt